Supply Chain
New research from Advisory Board, conducted in partnership with Staples Business, reveals how 102 health system supply chain and executive…
Hyland's Homeopathic issued a recall of its baby teething tablets April 14, about three months after the Food and Drug Administration discovered inconsistent amounts of the toxic substance belladonna in the products.
The Partnership for Safe Medicines, a nonprofit group advocating against importing cheaper drugs from foreign countries, has extensive ties to Pharmaceutical Research and Manufacturers of America — the drug industry's main lobbying group, reports Kaiser Health News.
A new market analysis from Visante shows no relationship between drug prices and the amount of rebates and discounts pharmacy benefit manufacturers negotiate with drugmakers.
As medical waste service providers increasingly insist on hospitals moving to an integrated waste stream pricing model, hospitals should consider implications that can arise from this practice, according to Eric Slimp, manager of purchased services for MD Buyline.
A new study estimates the global pharmerging market will be worth roughly $1.4 billion by 2025, up from $552.8 million in 2015.
The Food and Drug Administration on Monday approved Genentech's drug Tecentriq to treat advanced bladder cancer.
Minneapolis-based Medtronic will sell part of its patient monitoring and recovery unit to Dublin, Ohio-based Cardinal Health for $6.1 billion in cash, reports StarTribune.
Bristol-Myers Squibb Co. will license two of its drugs to Biogen and Roche for $470 million upfront, reports Reuters.
The Food and Drug Administration on Friday rejected Eli Lilly's experimental rheumatoid arthritis drug, baricitinib.
Federal investigations and public scrutiny over high drug prices won't stop Arthur Bedrosian, CEO of Lannett Co., from raising prices, reports The New York Times.